OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Zalcberg on the Rationale for Dose Escalation With Ripretinib in Advanced GIST

October 21st 2021

John Raymond Zalcberg, PhD, MBBS, discusses the rationale for intra-patient dose escalation with ripretinib, as was examined in the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.

Dr. Subudhi on the Integration of Antiandrogen Agents in mHSPC

October 21st 2021

Sumit K. Subudhi, MD, PhD, discusses the integration of antiandrogen agents in metastatic hormone-sensitive prostate cancer.

Dr. McKinney on the Expanding Role of BTK Inhibitors in MCL

October 21st 2021

Matthew S. McKinney, MD, discusses the expanding role of BTK inhibitors in mantle cell lymphoma.

Dr. Brayer on the Emergence of BiTEs and Bispecific Antibodies in Multiple Myeloma

October 21st 2021

Jason Brayer, MD, PhD, discusses the emergence of bispecific T-cell engagers and bispecific antibodies in multiple myeloma.

Dr. Danilov on the Safety Profile of Entospletinib Plus Obinutuzumab in CLL

October 21st 2021

Alexey V. Danilov, MD, PhD, discusses the safety profile of entospletinib plus obinutuzumab in chronic lymphocytic leukemia.

Dr. Zhen on the Need for Novel Therapies in Poorly Differentiated Small-Cell-Type NETs

October 21st 2021

David Zhen, MD, discusses the need for novel therapies in poorly differentiated small-cell-type neuroendocrine tumors.

Dr. Ghobrial on Future Efforts to Prevent the Development of Multiple Myeloma

October 20th 2021

Irene Ghobrial, MD, discusses future efforts to prevent the development of multiple myeloma.

Dr. Thompson on the Safety Profile of Pirtobrutinib in Patients With Richter Transformation

October 20th 2021

Meghan Thompson, MD, discusses the safety profile of pirtobrutinib in patients with Richter transformation.

Dr. Cheah on the Safety Profile of TG-1701 With and Without Ublituximab/Umbralisib in CLL

October 20th 2021

Chan Cheah, MBBS, discusses the toxicity profile of TG-1701 with and without ublituximab and umbralisib in patients with chronic lymphocytic leukemia.

Dr. Lee on the Current State of Molecular Testing in Early-Stage NSCLC

October 20th 2021

Jay Moon Lee, MD, discusses the current state of molecular testing in early-stage non–small cell lung cancer.

Dr. Patel on the Utility of Consolidative Durvalumab in Stage III NSCLC

October 20th 2021

Sandip P. Patel, MD, discusses the utility of consolidative durvalumab in stage III non–small cell lung cancer.

Dr. Secord on the Design of the OReO Trial in Ovarian Cancer

October 19th 2021

Angeles A. Secord, MD, discusses the design of the phase 3b OReO trial in ovarian cancer.

Dr. Ailawadhi on the Rationale for Evaluating Lisaftoclax in CLL

October 19th 2021

Sikander Ailawadhi, MD, discusses the rationale for evaluating lisaftoclax in chronic lymphocytic leukemia in an early phase 1 study.

Dr. Soares on Advances in the Management of Pancreatic NETs

October 19th 2021

Heloisa P. Soares, MD, PhD, discusses advances in the management of pancreatic neuroendocrine tumors.

Dr. Zurita-Saavedra on Moving Therapies From mCRPC to mHSPC

October 19th 2021

Amado J. Zurita-Saavedra, MD, discusses moving therapies utilized in metastatic castration-resistant prostate cancer into the treatment of patients with metastatic hormone-sensitive prostate cancer.

Dr. Weiss on the Rationale for the KRYSTAL-1 Trial in KRAS G12C–Mutated CRC

October 19th 2021

Jared Weiss, MD, discusses the rationale for the phase 1/2 KRYSTAL-1 trial in patients with KRAS G12C–mutated colorectal cancer.

Dr. Singh on the Potential Effects of Radiation Timing in Head and Neck Cancer

October 18th 2021

Anurag Singh, MD, discusses the potential effects of radiation timing in head and neck cancer.

Dr. Subudhi on Future Directions With Immunotherapy in Prostate Cancer

October 18th 2021

Sumit K. Subudhi, MD, PhD, discusses future directions with immunotherapy in prostate cancer.

Dr. Erba on Selecting Between Ibrutinib and Acalabrutinib in CLL

October 18th 2021

Harry Paul Erba, MD, PhD, discusses selecting between ibrutinib and acalabrutinib in chronic lymphocytic leukemia.

Dr. Kahl on the Potential Utility of Frontline CAR T-Cell Therapy in MCL

October 15th 2021

Brad S. Kahl, MD, discusses the potential utility of frontline CAR T-cell therapy in mantle cell lymphoma.